(Q33956314)

30 July 2017

1 reference

title

Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications (English)

1 reference

30 July 2017

0 references

Marcela V Karpuj

1

1 reference

PubMed ID

11738470

30 July 2017

Mark W Becher

series ordinal

2

1 reference

PubMed ID

11738470

30 July 2017

Lawrence Steinman

series ordinal

3

1 reference

30 July 2017

1 January 2002

1 reference

Neurochemistry International

30 July 2017

1 reference

30 July 2017

40

1 reference

30 July 2017

1

1 reference

30 July 2017

31-36

1 reference

Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

1 reference

7 January 2021

Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Distinct nuclear localization and activity of tissue transglutaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Specificity of guinea pig liver transglutaminase for amine substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

1 reference

7 January 2021

DRPLA aggregation and transglutaminase, revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Neurodegenerative diseases and transglutaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Amyloid-like inclusions in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Reversing neurodegeneration: a promise unfolds

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Glutamine repeats and neurodegenerative diseases: molecular aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Scrapie prions aggregate to form amyloid-like birefringent rods

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-0186%2801%2900060-2

7 January 2021

10.1016/S0197-0186(01)00060-2

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11738470